Description: Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Home Page: www.royaltypharma.com
RPRX Technical Analysis
110 East 59th Street
New York,
NY
10022
United States
Phone:
212 883 0200
Officers
| Name | Title |
|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman & CEO |
| Mr. Terrance P. Coyne | Exec. VP & CFO |
| Mr. George Wingate Lloyd | Exec. VP of Investments & Chief Legal Officer |
| Mr. Christopher Hite | Vice Chairman & Exec. VP |
| Dr. Marshall Urist M.D., Ph.D. | Exec. VP and Head of Research & Investments |
| Mr. Arthur R. McGivern J.D. | Exec. VP of Investments & Gen. Counsel |
| Ms. Kristin Stafford | Sr. VP & Chief Accounting Officer |
| Dr. James Folmar Reddoch Ph.D. | Exec. VP of Investments & Chief Scientific Officer |
| Mr. George Grofik C.F.A., CPA | Sr. VP and Head of Investor Relations & Communications |
| Ms. Alessandra Sassun | VP & Head of Human Capital |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 10.846 |
|---|---|
| Trailing PE: | 34.4386 |
| Price-to-Book MRQ: | 2.9935 |
| Price-to-Sales TTM: | 8.1383 |
| IPO Date: | 1993-03-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |